NEW YORK (GenomeWeb News) – The National Heart, Lung, and Blood Institute expects to provide up to $30 million to support a number of centers that will develop diagnostics or treatments for lung diseases and for sleep-disordered breathing.
The Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases Stage I (CADET 1) program is aimed at accelerating development of in vitro diagnostic technologies and validation of preclinical markers, as well as discovery of potential therapeutics.
NHLBI plans to award as many as 30 of the two-year grants, which will provide up to $300,000 per year in direct costs.
CADET 1 is the first stage of the program, and it will provide support for programs that bring together multi-disciplinary teams that will explore, validate, and select the best potential targets for use in diagnostics or therapeutics.
These targets should already have been identified and have some established correlation between target levels and human disease. The research should focus on selection and validation of the most promising, specific targets for future development.
The centers could use the funds for development of reagents for use in testing target levels and/or activity, such as RNAi or antibodies; development of in vitro systems to determine target activity, ideally with potential for conversion to high-throughput format; validation of preclinical and/or clinical markers for applications in early diagnosis and intervention in retrospective and/or prospective human population studies; development of patient populations most likely to respond to target inhibition; assessment of target activity in appropriate cellular systems.